Study Estimating the Clinical Difference Between 300 mg and 150 mg of Secukinumab Following Dose Escalation to 300 mg in Patients With Ankylosing Spondylitis Study Estimating the Clinical Difference Between 300 mg and 150 mg of Secukinumab Following Dose Esc ...
A Randomized, Double-blind, Parallel-group, Multicenter Study of Secukinumab to Compare 300 mg and 150 mg at Week 52 in Patients With Ankylosing Spondylitis Who Are Randomized to Dose Escalation After Not Achieving Inactive Disease During an Initial 16 Weeks of Open-label Treatment With Secukinumab 150 mg (ASLeap) A Randomized, Double-blind, Parallel-group, Multicenter Study of Secukinumab to Compare 300 mg and 1 ...